D
Diwakar Mohan
Researcher at Johns Hopkins University
Publications - 94
Citations - 1847
Diwakar Mohan is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 16, co-authored 70 publications receiving 881 citations.
Papers
More filters
Journal ArticleDOI
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis.
Adam L. Booth,Angus B. Reed,Sonia Ponzo,Arrash Yassaee,Mert Aral,David Plans,Alain B. Labrique,Diwakar Mohan +7 more
TL;DR: In this paper, a systematic review was conducted using standardized methodology, searching two electronic databases (PubMed and SCOPUS) for relevant literature published between 1st January 2020 and 9th July 2020.
Journal ArticleDOI
Tackling socioeconomic inequalities and non-communicable diseases in low-income and middle-income countries under the Sustainable Development agenda.
Louis W. Niessen,Louis W. Niessen,Diwakar Mohan,Jonathan Kweku Akuoku,Andrew J. Mirelman,Sayem Ahmed,Sayem Ahmed,Tracey Perez Koehlmoos,Tracey Perez Koehlmoos,Antonio J. Trujillo,Jahangir A. M. Khan,Jahangir A. M. Khan,David H. Peters +12 more
TL;DR: Reduction of health inequalities and NCDs should become key in the promotion of the overall SDG agenda and a sustained reduction of general inequalities in income status, education, and gender within and between countries would enhance worldwide equality in health.
Posted ContentDOI
Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis
Adam L. Booth,Angus B. Reed,Sonia Ponzo,Arrash Yassaee,Mert Aral,David Plans,Alain B. Labrique,Diwakar Mohan +7 more
TL;DR: A range of easily assessed parameters are valuable to predict elevated risk of severe illness and mortality as a result of COVID-19, including patient characteristics and detailed comorbidities, alongside the novel inclusion of real-time symptoms and vital measurements.
Journal ArticleDOI
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Vinodh Pillai,Kavitha Muralidharan,Wenzhao Meng,Asen Bagashev,Derek A. Oldridge,Jaclyn Rosenthal,John S. Van Arnam,J. Joseph Melenhorst,Diwakar Mohan,Amanda M. DiNofia,Minjie Luo,Sindhu Cherian,Jonathan R. Fromm,Gerald Wertheim,Andrei Thomas-Tikhonenko,Michele Paessler,Carl H. June,Eline T. Luning Prak,Vijay Bhoj,Stephan A. Grupp,Shannon L. Maude,Susan R. Rheingold +21 more
TL;DR: Prior therapy with the CD19-directed, bispecific T-cell engager blinatumomab was associated with a significantly higher rate of failure to achieve MRD- remission or subsequent loss of remission with antigen escape, and immunophenotypic heterogeneity and lineage plasticity were independent of underlying clonotype and cytogenetic abnormalities.
Journal ArticleDOI
Determinants of postnatal care use at health facilities in rural Tanzania: multilevel analysis of a household survey.
TL;DR: The role of individual and community-level variables on the use of postnatal health services, defined as a check up from a heath facility within 42 days of delivery, are examined in Tanzania using multilevel logistic regression analysis.